CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy

Journal of the National Cancer Institute

Volumn 88, Issue 9, 1996, Pages 607-611

  Cheng, Liang ^a   Sun, Jian ^b   Pretlow, Thomas G ^a   Culp, Jerilyn ^b   Yang, Ning Sun ^b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Agracetus   (United States)

^c 8520 University Green   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; COLLAGEN GEL; COMPLEMENTARY DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LUCIFERASE; PROSTATE SPECIFIC ANTIGEN;

ANIMAL MODEL; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA TRANSFECTION; GENE THERAPY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROMOTER REGION; PROSTATE CANCER; TRANSGENIC MOUSE;

ANIMALS; BETA-GALACTOSIDASE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; LUCIFERASES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0029871830     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.9.607     Document Type: Article

References (35)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995 [published erratum appears in CA Cancer J Clin 1995;45:127-8]. CA Cancer J Clin 1995;45:8-30.
2. Anderson WF. Human gene therapy. Science 1992;256:808-13.
3. Miller AD. Human gene therapy comes of age. Nature 1992;357:455-60.
4. Rosenberg SA. Gene therapy for cancer. JAMA 1992;17:2416-9.
5. Rosenberg SA. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10:180-99.
6. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer [see comment citation in Medline]. Lancet 1992;339:715-21.
7. Pardoll D. New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol 1992;4:619-23.
8. Blankenstein T, Rowley DA. Schreiber H. Cytokines and cancer: experimental systems. Curr Opin Immunol 1991;3:694-8.
9. Sun WH, Burkholder JK, Sun J, Culp J, Turner J, Lu XG, et al. In vivo cytokine gene transfer reduces tumor growth in mice. Proc Natl Acad Sci U S A 1995;92:2889-93.
10. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
11. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
12. Gotumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
13. Karp SE. Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J Immunol 1993;150:896-908.
14. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, et al. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993;85:394-8.
15. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM. et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54:6049-52.
16. Helms SR, Pretlow TG, Bueschen AJ, Lloyd KL, Murad TM. Separation of cells with histochemically demonstrable acid phosphatase activity from suspensions of cells from human prostatic carcinomas in an isokinetic gradient of Ficoll in tissue culture medium. Cancer Res 1976;36(2Pt 1):481-6.
17. Yang J, Richards J, Guzman R. Imagawa W, Nandi S. Sustained growth in primary culture of normal mammary epithelial cells embedded in collagen gels. Proc Natl Acad Sci USA 1980;77:2088-92.
18. Yang NS, Kube D, Park C, Furmanski P. Growth of human mammary epithelial cells on collagen gel surface. Cancer Res 1981;41: 4093-100.
19. Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993;90:4455-9.
20. Jiao S, Cheng L, Wolff JA, Yang NS, Particle bombardment-mediated gene transfer and expression in rat brain tissues. Biotechnology 1993;11:497-502.
21. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci U S A 1990;87:9568-72.
22. Yang NS, Sun WH. Gene gun and other nonviral approaches for cancer gene therapy. Nat Med 1995;1:481-3.
23. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
24. R&D System. Cytokine Bulletin. Spring Issue: 1994:3-4.
25. Lin W, Pretlow TP, Pretlow TG 3d. Gulp LA. Development of micrometastasis: earliest events detected with bacterial lacZ gene-tagged tumor cells. J Natl Cancer Inst 1990;82:1497-503.
26. Yang NS. Gene transfer into mammalian somatic cells in vivo. Crit Rev Biotechnol 1992;12:335-56.
27. Thompson TA, Gould MN, Burkholder JK, Yang NS. Transient promoter activity in primary rat mammary epithelial cells evaluated using particle bombardment gene transfer. In Vitro Cell Dev Biol 1993;29A:165-70.
28. Burkholder JK, Decker J. Yang NS. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer. J Immunol Methods 1993;165:149-56.
29. Yang NS, Burkholder JK, Cheng L, Ziegelhoffer PR. Accell particle bombardment for gene transfer as a useful gene therapy technique. In: Hui KM, editor. Immunotherapeutic approaches for the treatment of cancer. River Edge (NJ): World Scientific Publishing Co., 1995:130-61.
30. Yang NS. DeLuna C, Cheng L. Gene transfer via particle bombardment: applications of the Accell gene gun. In: Wolff JA, editor. Gene therapeutics: methods and applications of direct gene transfer. Boston: Birkhauser, 1994:193-209.
31. Weber JS, Jay G, Tanaka K, Rosenberg SA. Immunotherapy of murine tumor with interleukin 2. Increased sensitivity after MHC class 1 gene transfection. J Exp Med 1987;166: 1716-33.
32. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sei U S A 1993;90:3539-43.
33. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
34. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151:622-8.
35. Tjota A, Zhang YQ, Piedmonte MR, Lee CL. Adoptive immunotherapy using lymphokineactivated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor. J Urol 1991; 146:177-83.